Phillip B. Donenberg

CIK: 0001238120

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

SNSE

Sensei Biotherapeutics, Inc.

Director

TECX

Tectonic Therapeutic, Inc.

Director

TSHA

Taysha Gene Therapies, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

SNSE
Sensei Biotherapeutics, Inc.
Jun 10, 2026
Award(A)
Stock Option (right to buy)
Direct
12.5K shares-
TECX
Tectonic Therapeutic, Inc.
Jun 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
10.2K shares-
TSHA
Taysha Gene Therapies, Inc.
Jun 1, 2026
Award(A)
Direct
21.3K shares-
SNSE
Sensei Biotherapeutics, Inc.
Apr 10, 2026
Award(A)
Stock Option (right to buy)
Direct
23.1K shares-
SNSE
Sensei Biotherapeutics, Inc.
Feb 13, 2026
Award(A)
Stock Option (right to buy)
Direct
1.9K shares-
TECX
Tectonic Therapeutic, Inc.
Jun 9, 2025
Award(A)
Stock Option (Right to Buy)
Direct
10.2K shares-
TSHA
Taysha Gene Therapies, Inc.
Jun 2, 2025
Award(A)
Direct
56.6K shares-

		Type	Shares	Price		Ownership
Jun 10, 2026	SNSE Sensei Biotherapeutics, Inc.	Award(A) Stock Option (right to buy)	12,500	-	-	Direct
Jun 9, 2026	TECX Tectonic Therapeutic, Inc.	Award(A) Stock Option (Right to Buy)	10,200	-	-	Direct
Jun 1, 2026	TSHA Taysha Gene Therapies, Inc.	Award(A)	21,335	-	$0	Direct
Apr 10, 2026	SNSE Sensei Biotherapeutics, Inc.	Award(A) Stock Option (right to buy)	23,100	-	-	Direct
Feb 13, 2026	SNSE Sensei Biotherapeutics, Inc.	Award(A) Stock Option (right to buy)	1,900	-	-	Direct
Jun 9, 2025	TECX Tectonic Therapeutic, Inc.	Award(A) Stock Option (Right to Buy)	10,200	-	-	Direct
Jun 2, 2025	TSHA Taysha Gene Therapies, Inc.	Award(A)	56,623	-	-	Direct

1-7 of 7 transactions

About Donenberg Phillip B.

Donenberg Phillip B. (SEC CIK 0001238120) files insider reports with the SEC as Director of Sensei Biotherapeutics, Inc. (SNSE), Director of Tectonic Therapeutic, Inc. (TECX) and Director of Taysha Gene Therapies, Inc. (TSHA).

Signal8 holds 8 ownership filings by Donenberg Phillip B. (1 Form 3, 7 Form 4), filed between Jun 4, 2025 and Jun 12, 2026. Those filings report 7 transactions, from Jun 2, 2025 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Donenberg Phillip B.'s filings is in DALLAS, TX.

Recent filings by Donenberg Phillip B.

Jun 10, 2026: Grant or award of SNSE derivative securities (Form 4, code A).
Jun 9, 2026: Grant or award of TECX derivative securities (Form 4, code A).
Jun 1, 2026: Grant or award of TSHA shares (Form 4, code A).
Apr 10, 2026: Grant or award of SNSE derivative securities (Form 4, code A).
Feb 13, 2026: Grant or award of SNSE derivative securities (Form 4, code A).

Other insiders filing for Sensei Biotherapeutics, Inc. (SNSE)

Gerry Christopher, President & PEO
Holmen Bob, Director
Cambrian BioPharma Inc, 10% Owner
Peyer James, 10% Owner
MILLENNIUM MANAGEMENT LLC, 10% Owner
RICKS THOMAS G, Director

How to read Form 4 transaction codes